{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:05:44Z","timestamp":1773288344511,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T00:00:00Z","timestamp":1468454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s11606-016-3772-5","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T15:39:24Z","timestamp":1468510764000},"page":"1338-1344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years"],"prefix":"10.1007","volume":"31","author":[{"given":"Xian Wen","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Lipold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Foucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Sikon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Brainard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Belinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Nottingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Rothberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,14]]},"reference":[{"key":"3772_CR1","unstructured":"International Agency for Research on Cancer GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. Available at: http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx . Accessed 31 May 2016."},{"issue":"12","key":"3772_CR2","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1093\/annonc\/mdr015","volume":"22","author":"M Arbyn","year":"2011","unstructured":"Arbyn M, Castellsagu\u00e9 X, de Sanjos\u00e9 S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2011;22(12):2675\u201386. doi: 10.1093\/annonc\/mdr015 .","journal-title":"Ann Oncol Off J Eur Soc Med Oncol ESMO"},{"key":"3772_CR3","unstructured":"National Cancer Institute. SEER cancer statistics review, 1975\u20132009 (vintage 2009 populations). Available at: http:\/\/seer.cancer.gov\/csr\/1975_2009_pops09 . Accessed May 31, 2016."},{"key":"3772_CR4","unstructured":"American Cancer Society. Cancer Facts & Figures 2015. 2015."},{"issue":"3","key":"3772_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3322\/caac.21139","volume":"62","author":"D Saslow","year":"2012","unstructured":"Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147\u201372. doi: 10.3322\/caac.21139 .","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"3772_CR6","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa071430","volume":"357","author":"M-H Mayrand","year":"2007","unstructured":"Mayrand M-H, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579\u201388. doi: 10.1056\/NEJMoa071430 .","journal-title":"N Engl J Med"},{"issue":"5 Suppl 1","key":"3772_CR7","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1097\/LGT.0b013e318285423c","volume":"17","author":"HA Katki","year":"2013","unstructured":"Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S28\u201335. doi: 10.1097\/LGT.0b013e318285423c .","journal-title":"J Low Genit Tract Dis"},{"issue":"1","key":"3772_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(11)70296-0","volume":"13","author":"DC Rijkaart","year":"2012","unstructured":"Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78\u201388. doi: 10.1016\/S1470-2045(11)70296-0 .","journal-title":"Lancet Oncol"},{"issue":"12","key":"3772_CR9","doi-asserted-by":"publisher","first-page":"880","DOI":"10.7326\/0003-4819-156-12-201206190-00424","volume":"156","author":"VA Moyer","year":"2012","unstructured":"Moyer VA, US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156(12):880\u201391. doi: 10.7326\/0003-4819-156-12-201206190-00424 . W312.","journal-title":"Ann Intern Med"},{"issue":"5","key":"3772_CR10","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/AOG.0b013e318277c92a","volume":"120","author":"Committee on Practice Bulletins\u2014Gynecology","year":"2012","unstructured":"Committee on Practice Bulletins\u2014Gynecology. ACOG Practice Bulletin Number 131: screening for cervical cancer. Obstet Gynecol. 2012;120(5):1222\u201338. doi: 10.1097\/AOG.0b013e318277c92a .","journal-title":"Obstet Gynecol"},{"issue":"4","key":"3772_CR11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1097\/AOG.0b013e3182883a34","volume":"121","author":"LS Massad","year":"2013","unstructured":"Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121(4):829\u201346. doi: 10.1097\/AOG.0b013e3182883a34 .","journal-title":"Obstet Gynecol"},{"issue":"7","key":"3772_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1001\/jamainternmed.2014.1368","volume":"174","author":"K Smith-McCune","year":"2014","unstructured":"Smith-McCune K. Choosing a screening method for cervical cancer: Papanicolaou testing alone or with human papillomavirus testing. JAMA Intern Med. 2014;174(7):1027\u20138. doi: 10.1001\/jamainternmed.2014.1368 .","journal-title":"JAMA Intern Med"},{"issue":"24","key":"3772_CR13","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMcp1210379","volume":"369","author":"M Schiffman","year":"2013","unstructured":"Schiffman M, Solomon D. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting. N Engl J Med. 2013;369(24):2324\u201331. doi: 10.1056\/NEJMcp1210379 .","journal-title":"N Engl J Med"},{"issue":"5","key":"3772_CR14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ijc.21955","volume":"119","author":"J Cuzick","year":"2006","unstructured":"Cuzick J, Clavel C, Petry K-U, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095\u2013101. doi: 10.1002\/ijc.21955 .","journal-title":"Int J Cancer"},{"issue":"9399","key":"3772_CR15","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/S0140-6736(03)14955-0","volume":"362","author":"J Cuzick","year":"2003","unstructured":"Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362(9399):1871\u20136. doi: 10.1016\/S0140-6736(03)14955-0 .","journal-title":"Lancet"},{"issue":"7","key":"3772_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(11)70145-0","volume":"12","author":"HA Katki","year":"2011","unstructured":"Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663\u201372. doi: 10.1016\/S1470-2045(11)70145-0 .","journal-title":"Lancet Oncol"},{"key":"3772_CR17","doi-asserted-by":"crossref","first-page":"c1804","DOI":"10.1136\/bmj.c1804","volume":"340","author":"A Anttila","year":"2010","unstructured":"Anttila A, Kotaniemi-Talonen L, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ. 2010;340:c1804.","journal-title":"BMJ"},{"issue":"23","key":"3772_CR18","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/jnci\/djp367","volume":"101","author":"M Leinonen","year":"2009","unstructured":"Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst. 2009;101(23):1612\u201323. doi: 10.1093\/jnci\/djp367 .","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"3772_CR19","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1056\/NEJMoa0808516","volume":"360","author":"R Sankaranarayanan","year":"2009","unstructured":"Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385\u201394. doi: 10.1056\/NEJMoa0808516 .","journal-title":"N Engl J Med"},{"key":"3772_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62218-7","author":"G Ronco","year":"2013","unstructured":"Ronco G, Dillner J, Elfstr\u00f6m KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2013. doi: 10.1016\/S0140-6736(13)62218-7 .","journal-title":"Lancet"},{"issue":"9","key":"3772_CR21","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S1470-2045(11)70188-7","volume":"12","author":"PE Castle","year":"2011","unstructured":"Castle PE, Stoler MH, Wright TCJ, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880\u201390. doi: 10.1016\/S1470-2045(11)70188-7 .","journal-title":"Lancet Oncol"},{"key":"3772_CR22","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","volume":"337","author":"J Dillner","year":"2008","unstructured":"Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.","journal-title":"BMJ"},{"key":"3772_CR23","unstructured":"Vesco KK, Whitlock EP, Eder M, et al. Screening for Cervical Cancer: A Systematic Evidence Review for the US Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK66099\/ . Accessed 31 May 2016."},{"issue":"2","key":"3772_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","volume":"136","author":"WK Huh","year":"2015","unstructured":"Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136(2):178\u201382. doi: 10.1016\/j.ygyno.2014.12.022 .","journal-title":"Gynecol Oncol"},{"issue":"10","key":"3772_CR25","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1001\/jamainternmed.2014.4021","volume":"174","author":"S Feldman","year":"2014","unstructured":"Feldman S. Human papillomavirus testing for primary cervical cancer screening: is it time to abandon Papanicolaou testing? JAMA Intern Med. 2014;174(10):1539\u201340. doi: 10.1001\/jamainternmed.2014.4021 .","journal-title":"JAMA Intern Med"},{"issue":"11","key":"3772_CR26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1001\/jama.285.11.1500","volume":"285","author":"MH Stoler","year":"2001","unstructured":"Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA J Am Med Assoc. 2001;285(11):1500\u20135.","journal-title":"JAMA J Am Med Assoc"},{"issue":"5","key":"3772_CR27","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1309\/PT3PNC1QL2F4D2VL","volume":"127","author":"PE Castle","year":"2007","unstructured":"Castle PE, Stoler MH, Solomon D, Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol. 2007;127(5):805\u201315. doi: 10.1309\/PT3PNC1QL2F4D2VL .","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"3772_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/pgp.0b013e31805152ab","volume":"26","author":"JD Carreon","year":"2007","unstructured":"Carreon JD, Sherman ME, Guill\u00e9n D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2007;26(4):441\u20136. doi: 10.1097\/pgp.0b013e31805152ab .","journal-title":"Int J Gynecol Pathol Off J Int Soc Gynecol Pathol"},{"issue":"1","key":"3772_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/AOG.0b013e31818f5008","volume":"113","author":"PE Castle","year":"2009","unstructured":"Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113(1):18\u201325. doi: 10.1097\/AOG.0b013e31818f5008 .","journal-title":"Obstet Gynecol"},{"issue":"6","key":"3772_CR30","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1097\/AOG.0b013e3181fe777f","volume":"116","author":"A-B Moscicki","year":"2010","unstructured":"Moscicki A-B, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116(6):1373\u201380. doi: 10.1097\/AOG.0b013e3181fe777f .","journal-title":"Obstet Gynecol"},{"issue":"16","key":"3772_CR31","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","volume":"287","author":"D Solomon","year":"2002","unstructured":"Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA J Am Med Assoc. 2002;287(16):2114\u20139.","journal-title":"JAMA J Am Med Assoc"},{"key":"3772_CR32","unstructured":"Qiagen. digene HC2 High-Risk HPV DNA Test. Available at: http:\/\/www.qiagen.com\/products\/catalog\/assay-technologies\/complete-assay-kits\/hpv-testing\/digene-hc2-high-risk-hpv-dna-test#productdetails . Accessed 31 May 2016."},{"key":"3772_CR33","unstructured":"Centers for Medicare and Medicaid Services. Fee Schedules \u2013 General Information. Available at: http:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/FeeScheduleGenInfo\/index.html . Accessed 31 May 2016."},{"issue":"4","key":"3772_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.7326\/M14-1043","volume":"161","author":"RB Perkins","year":"2014","unstructured":"Perkins RB, Stier EA. Should US women be screened for cervical cancer with pap tests, HPV tests, or both? Ann Intern Med. 2014;161(4):295\u20137. doi: 10.7326\/M14-1043 .","journal-title":"Ann Intern Med"},{"issue":"3","key":"3772_CR35","doi-asserted-by":"publisher","first-page":"184.e1","DOI":"10.1016\/j.ajog.2012.11.020","volume":"208","author":"JT Cox","year":"2013","unstructured":"Cox JT, Castle PE, Behrens CM, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16\/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208(3):184.e1\u2013e184.e11. doi: 10.1016\/j.ajog.2012.11.020 .","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"3772_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.7326\/0003-4819-155-10-201111150-00376","volume":"155","author":"EP Whitlock","year":"2011","unstructured":"Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the US Preventive Services Task Force. Ann Intern Med. 2011;155(10):687\u201397. doi: 10.7326\/0003-4819-155-10-201111150-00376 . W214-W215.","journal-title":"Ann Intern Med"},{"issue":"3","key":"3772_CR37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ijc.21897","volume":"119","author":"M-H Mayrand","year":"2006","unstructured":"Mayrand M-H, Duarte-Franco E, Coutl\u00e9e F, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer. 2006;119(3):615\u201323. doi: 10.1002\/ijc.21897 .","journal-title":"Int J Cancer"},{"issue":"3","key":"3772_CR38","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF03404377","volume":"101","author":"A Vijayaraghavan","year":"2010","unstructured":"Vijayaraghavan A, Efrusy MB, Mayrand M-H, Santas CC, Goggin P. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Qu\u00e9bec, Canada. Can J Public Health. 2010;101(3):220\u20135.","journal-title":"Can J Public Health"},{"issue":"2","key":"3772_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ygyno.2008.08.030","volume":"112","author":"A Vijayaraghavan","year":"2009","unstructured":"Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol Oncol. 2009;112(2):377\u201383. doi: 10.1016\/j.ygyno.2008.08.030 .","journal-title":"Gynecol Oncol"},{"issue":"4","key":"3772_CR40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/01.AOG.0000120143.50098.c7","volume":"103","author":"SJ Goldie","year":"2004","unstructured":"Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103(4):619\u201331. doi: 10.1097\/01.AOG.0000120143.50098.c7 .","journal-title":"Obstet Gynecol"},{"issue":"20","key":"3772_CR41","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1056\/NEJMsa044278","volume":"353","author":"SJ Goldie","year":"2005","unstructured":"Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353(20):2158\u201368. doi: 10.1056\/NEJMsa044278 .","journal-title":"N Engl J Med"},{"issue":"24","key":"3772_CR42","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1001\/jama.285.24.3107","volume":"285","author":"SJ Goldie","year":"2001","unstructured":"Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA J Am Med Assoc. 2001;285(24):3107\u201315.","journal-title":"JAMA J Am Med Assoc"},{"issue":"12","key":"3772_CR43","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/jnci\/dji162","volume":"97","author":"JJ Kim","year":"2005","unstructured":"Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst. 2005;97(12):888\u201395. doi: 10.1093\/jnci\/dji162 .","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"3772_CR44","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1001\/jama.287.18.2372","volume":"287","author":"JS Mandelblatt","year":"2002","unstructured":"Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA J Am Med Assoc. 2002;287(18):2372\u201381.","journal-title":"JAMA J Am Med Assoc"},{"key":"3772_CR45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1741-7015-7-69","volume":"7","author":"SL Kulasingam","year":"2009","unstructured":"Kulasingam SL, Rajan R, St Pierre Y, Atwood CV, Myers ER, Franco EL. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Med. 2009;7:69. doi: 10.1186\/1741-7015-7-69 .","journal-title":"BMC Med"},{"issue":"1","key":"3772_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/sj.bjc.6601884","volume":"91","author":"C Sherlaw-Johnson","year":"2004","unstructured":"Sherlaw-Johnson C, Philips Z. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer. 2004;91(1):84\u201391. doi: 10.1038\/sj.bjc.6601884 .","journal-title":"Br J Cancer"},{"issue":"9","key":"3772_CR47","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/ijc.25211","volume":"127","author":"J Berkhof","year":"2010","unstructured":"Berkhof J, Coup\u00e9 VM, Bogaards JA, et al. The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer. 2010;127(9):2147\u201358. doi: 10.1002\/ijc.25211 .","journal-title":"Int J Cancer"},{"key":"3772_CR48","volume":"344","author":"IMCM Kok de","year":"2012","unstructured":"de Kok IMCM, van Rosmalen J, Dillner J, et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ. 2012;344, e670.","journal-title":"BMJ"},{"issue":"6","key":"3772_CR49","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1471-0528.2011.03228.x","volume":"119","author":"J Rosmalen van","year":"2012","unstructured":"van Rosmalen J, de Kok IMCM, van Ballegooijen M. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG Int J Obstet Gynaecol. 2012;119(6):699\u2013709. doi: 10.1111\/j.1471-0528.2011.03228.x .","journal-title":"BJOG Int J Obstet Gynaecol"},{"issue":"3","key":"3772_CR50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1043\/1543-2165-134.3.331","volume":"134","author":"GM Eversole","year":"2010","unstructured":"Eversole GM, Moriarty AT, Schwartz MR, et al. Practices of participants in the college of american pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. Arch Pathol Lab Med. 2010;134(3):331\u20135. doi: 10.1043\/1543-2165-134.3.331 .","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"3772_CR51","first-page":"945","volume":"9","author":"S Ratnam","year":"2000","unstructured":"Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomark Prev. 2000;9(9):945\u201351.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"14","key":"3772_CR52","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.288.14.1749","volume":"288","author":"SL Kulasingam","year":"2002","unstructured":"Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA J Am Med Assoc. 2002;288(14):1749\u201357.","journal-title":"JAMA J Am Med Assoc"},{"issue":"7","key":"3772_CR53","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(09)70156-1","volume":"10","author":"HC Kitchener","year":"2009","unstructured":"Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672\u201382. doi: 10.1016\/S1470-2045(09)70156-1 .","journal-title":"Lancet Oncol"},{"issue":"4","key":"3772_CR54","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1309\/AJCPTUS5EXAS6DKZ","volume":"136","author":"TCJ Wright","year":"2011","unstructured":"Wright TCJ, Stoler MH, Sharma A, et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011;136(4):578\u201386. doi: 10.1309\/AJCPTUS5EXAS6DKZ .","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"3772_CR55","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1128\/JCM.05400-11","volume":"50","author":"AA Wong","year":"2012","unstructured":"Wong AA, Fuller J, Pabbaraju K, Wong S, Zahariadis G. Comparison of the hybrid capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreservCyt medium. J Clin Microbiol. 2012;50(1):25\u20139. doi: 10.1128\/JCM.05400-11 .","journal-title":"J Clin Microbiol"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-016-3772-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-016-3772-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-016-3772-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T23:48:11Z","timestamp":1600904891000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-016-3772-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,14]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["3772"],"URL":"https:\/\/doi.org\/10.1007\/s11606-016-3772-5","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,14]]}}}